1. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review;Abdul-Quader;AIDS Behav.,2013
2. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices;Afdhal;J. Viral Hepat.,2013
3. Arends, J., Brinkman, K., Richter, C., et al., 2013. High on treatment virologic response rates with boceprevir or telaprevir in naive and pretreated HIV/HCV coinfected patients. In: 14th EACS, Brussels, Belgium, October 16–19, 2013 (Abstract PS13/37).
4. Backus, L., Belperio, P., Shahoumian, T., Cheung, R., Mole, L., in press. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol. Ther.
5. Reproductive options for HIV-serodiscordant couples;Barreiro;AIDS Rev.,2006